2023 Midwest Precision Oncology Symposium

Livonia, MI US
September 30, 2023

This program, the 2023 Midwest Precision Oncology Symposium, is an accredited continuing education activity designed to improve the care of cancer patients by educating cancer care providers about precision oncology. This oncology conference features leading experts in the field of precision oncology who will provide a comprehensive overview of the implications of actionable molecular alterations across common malignancies.
This activity is designed to facilitate learning, improve knowledge retention, and inspire participants to implement the newly acquired knowledge into their clinical practice. Through didactic lectures, case-based discussions, and interactive questions and answer sessions, participants will be able to ask relevant questions, clarify concerns, and network with expert faculties. 
During this live meeting, expert faculty will review recent advances, as well as key abstract findings relevant to precision oncology from the ASCO2023 annual meeting and place those findings into clinical context during the case-based discussions and questions and answer sessions, with a focus on how those findings might impact patient care. 

 

Program Venue:

Embassy Suites by Hilton Detroit Livonia Novi

19525 Victor Pkwy, Livonia, MI 48152

Target Audience

  • Hematologists Oncologists
  • Oncology Fellows
  • NPs/PAs
  • Pharmacists
  • Nurses
  • Physician Assistants
  • Researchers and others

 

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Identify frequent molecular abnormalities across several common malignancies and understand the appropriate timing of testing to detect these abnormalities.
  • Interpret results of next-generation sequencing and other biomarkers predictive of response to targeted therapies and recognize the challenges involved.
  • Explain the role, including advantages and disadvantages, of different testing methodologies available for the selection of targeted therapies. 
  • Plan optimal molecular-targeted treatment strategies for the treatment of cancer.
  • Outline emerging research, the mechanism of action, and the role of novel molecular-targeted therapies in the clinical investigation of cancer patients.
Course summary
Available credit: 
  • 5.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 5.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 5.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.75 Contact Hours.
Course opens: 
03/27/2023
Course expires: 
12/30/2023
Event starts: 
09/30/2023 - 8:00am PDT
Event ends: 
09/30/2023 - 3:00pm PDT
Cost:
$200.00
Add to calendar: 

Conference Chair: Dr. Ulka Vaishampayan

September 30, 2023

All times are listed in Eastern Time (ET)

07:00 – 08:00 AM: REGISTRATION, BREAKFAST, EXHIBITS

08:00 – 08:05 AM: Welcome - Ulka Vaishampayan, MD

08:05 – 08:15 AM: Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD

08:15 – 09:30 AM: SESSION 1 - PRECISION ONCOLOGY – GENERAL CONCEPTS

Moderator: Ulka Vaishampayan, MD

08:15 – 08:30 AM: Liquid Biopsy - Ulka Vaishampayan, MD

08:30 – 08:40 AM: Q and A

08:40 – 08:55 AM: Germline Testing for Hereditary Cancers - Dana Zakalik, MD

08:55 – 09:30 AM: Panel Discussion - Dana Zakalik, MD; Dongping Shi, MD; Ulka Vaishampayan, MD

09:30 – 10:30 AM: SESSION 2 - LUNG CANCER

Moderator: Dipesh Uprety, MD

09:30 – 09:45 AM: Keynote Speech - Shirish M. Gadgeel, MD

09:45 – 10:30 AM: Panel Discussion - Greg Kalemkerian, MD; Hirva Mamdani, MD; Ishmael Jaiyesimi, DO, MS, FACP

10:30 – 11:00 AM: BREAK AND EXHIBITS

11:00 AM – 12:00 PM: SESSION 3 - BREAST CANCER

Moderator: Hadeel Assad, MD

11:00 – 11:15 AM: Precision Therapy in Breast Cancer - Norah Lynn Henry, MD, PhD

11:15 AM – 12:00 PM: Panel Discussion - Daniel Isaac, MS, DO; Dana Zakalik, MD; Hadeel Assad, MD; Norah Lynn Henry, MD, PhD

12:00 – 01:00 PM: LUNCH AND EXHIBITS

Industry Sponsored Symposium Sponsored by Merck

Presentation Title: A Treatment Option for Certain Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Speaker: Amit Mehta, MD is a GU medical oncologist at Premier Hematology & Tele-Oncology Center in Cary, NC

This program is not part of the CME activity.

01:00 – 02:00 PM: SESSION 4 - GU ONCOLOGY

Moderator: Ulka Vaishampayan, MD

01:00 – 01:15 PM: Keynote Speech - Ulka Vaishampayan, MD

01:15 – 02:00 PM: Panel Discussion - Clara Hwang, MD; Jason Hafron, MD; Daniel Isaac, MS, DO; Dongping Shi, MD

02:00 – 03:30 PM: SESSION 5 - HEMATOLOGY

Moderator: Jeffrey Zonder, MD

02:00 – 02:30 PM: Precision Therapy in Myeloma - Jeffrey Zonder, MD

02:30 – 02:45 PM: Q and A

02:45 – 03:15 PM: Lymphoma - Abhinav Deol, MD

03:15 – 03:30 PM: Q and A

Embassy Suites by Hilton Detroit Livonia Novi
19525 Victor Parkway
Livonia, MI 48152
United States
+1 (734) 462-6000

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.

Ulka Vaishampayan, MD

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Exelixis;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with sanofi;.
Speaker/Topic Presenter(s)

Abhinav Deol, MD

has a financial relationship (Other) with Kite/Gilead;.
has a financial relationship (Other) with Janssen;.

Shirish Gadgeel, MD

has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Professional Services) with GSK;.
has a financial relationship (Professional Services) with Janssen Oncology;.
has a financial relationship (Professional Services) with Astra-Zeneca;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Travel) with Mirati;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Arcus;.
has a financial relationship (Professional Services) with Esai;.
has a financial relationship (Professional Services) with Genentech/Roche;.
has a financial relationship (Professional Services) with Mirati;.
has a financial relationship (Professional Services) with Eli Lilly;.

Jason Hafron

has a financial relationship (Grant Or Contract) with Dendreon Pharmaceuticals LLC;.
has a financial relationship (Professional Services) with Janssen Biotech Inc;.
has a financial relationship (Professional Services) with Merck & Co. Inc.;.
has a financial relationship (Grant Or Contract) with Myriad Genetics Inc.;.
has a financial relationship (Professional Services) with Pfizer Inc.;.
has a financial relationship (Professional Services) with Tolmar Pharmaceuticals Inc.;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Dendreon Pharmaceuticals LLC;.
has a financial relationship (Grant Or Contract) with Immunis.AI;.
has a financial relationship (Professional Services) with Lantheus;.
has a financial relationship (Professional Services) with Myriad Genetics Inc.;.
has a financial relationship (Grant Or Contract) with Nucleix;.
has a financial relationship (Professional Services) with Progenics Pharmaceuticals, Inc.;.
has a financial relationship (Professional Services) with Lynx DX;.
has a financial relationship (Professional Services) with Amgen;.
has a financial relationship (Professional Services) with Blue Earth Diagnostics;.
has a financial relationship (Professional Services) with Immunis.AI;.
has a financial relationship (Grant Or Contract) with Lipella Pharmaceuticals LLC;.
has a financial relationship (Grant Or Contract) with miR Scientific Inc.;.
has a financial relationship (Grant Or Contract) with Myovant Sciences Inc.;.
has a financial relationship (Professional Services) with Procept-Biorobotic;.
has a financial relationship (Professional Services) with Promaxo;.
has a financial relationship (Grant Or Contract) with Astellas Pharma Inc;.
has a financial relationship (Professional Services) with Eli Lilly and Company;.
has a financial relationship (Grant Or Contract) with Janssen Biotech Inc;.
has a financial relationship (Grant Or Contract) with Merck & Co. Inc.;.
has a financial relationship (Professional Services) with Myovant Sciences Inc.;.
has a financial relationship (Grant Or Contract) with Pfizer Inc.;.
has a financial relationship (Professional Services) with Urogen Pharma Inc.;.
has a financial relationship (Professional Services) with Astellas Pharma Inc;.
has a financial relationship (Grant Or Contract) with Bayer;.

Norah Henry

has a financial relationship (Other) with Myovant Sciences;.
has a financial relationship (Other) with AstraZeneca;.

Clara Hwang, MD, Senior Staff Physician, Assistant Professor

has a financial relationship (Other) with TEMPUS;.
has a financial relationship (Grant Or Contract) with Bausch Health;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Travel) with Merck;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Stock) with Johnson and Johnson;.
has a financial relationship (Grant Or Contract) with Genentech;.

Daniel Isaac

has no relevant financial relationships to disclose at this time.

Ishmael Jaiyesimi

has no relevant financial relationships to disclose at this time.

Gregory Kalemkerian, MD

has a financial relationship (Grant Or Contract) with Takeda;.
has a financial relationship (Grant Or Contract) with Blueprint;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Daiichi;.
has a financial relationship (Grant Or Contract) with Cullinan;.

Hirva Mamdani

has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Professional Services) with Zentalis;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with AstraZeneca;.

Dongping Shi

has no relevant financial relationships to disclose at this time.

Ulka Vaishampayan, MD

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Exelixis;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with sanofi;.

Dana Zakalik, M.D. Medical Oncology

has no relevant financial relationships to disclose at this time.

Jeffrey Zonder

has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Professional Services) with Alexion;.
has a financial relationship (Professional Services) with Intellia;.
has a financial relationship (Professional Services) with Regeneron;.
has a financial relationship (Employment) with BMS;.
Moderator(s)

Hadeel Assad

has a financial relationship (Other) with Stemline;.
has a financial relationship (Other) with Gilead;.

Dipesh Uprety, MD, FACP

has a financial relationship (Professional Services) with Daiichi Sankyo, Astrazeneza, and Sanofi.;.

Ulka Vaishampayan, MD

has a financial relationship (Professional Services) with Exelixis;.
has a financial relationship (Professional Services) with sanofi;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Pfizer;.

Jeffrey Zonder

has a financial relationship (Professional Services) with Alexion;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Professional Services) with Intellia;.
has a financial relationship (Employment) with BMS;.
has a financial relationship (Professional Services) with Regeneron;.
has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Grant Or Contract) with Janssen;.
Planning committee(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.

Available Credit

  • 5.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 5.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 5.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.75 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$200.00
Please login or register to take this course.

REGISTRATION FEES 

Physicians (non-industry) - $200

Non-physician HCP (non-industry) - $75

Industry representatives - $850

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

Cancellation Policy

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is cancelled six weeks before the conference.
  • No refunds will be issued if registration is cancelled after that date.  

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.